Author: Shah MH, Kulke MH, Goldner WS, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Chan J, Eads J, Engstrom PF, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns J, Ogba N, Zuccarino-Catania G
Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
Type of cancer: Brain, Colorectal, Gastrointestinal, Head and neck and oropharyngeal, Lung
Patient population: Adult
Location: International
This is a clinical practice guideline for patients with neuroendocrine or adrenal tumours. The guideline discusses the diagnosis, staging, treatment, and follow-up of patients with sporadic neuroendocrine tumours, originating from organs such as the lungs, thymus, and gastrointestinal (GI) tract. The guideline also examines the role of the genetic syndrome, multiple endocrine neoplasia (MEN), in developing parathyroid, pituitary, and pancreatic tumours.
AGREE II - Quality of Reporting Assessment:
Scope and purpose: 72.2%
Applicability: 33.3%
Stakeholder involvement: 58.3%
Editorial independence: 87.5%
Rigour: 67.7%
Clarity presentation: 69.4%
